Trials / Completed
CompletedNCT06256562
A Study of GZR18 Injection in Obese/Overweight Patients
A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 340 (actual)
- Sponsor
- Gan and Lee Pharmaceuticals, USA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR18 | Titrated to dose 1, dose 2, dose 3 or dose 4 |
| OTHER | Placebo | Administered the same volume as GZR18 |
Timeline
- Start date
- 2023-06-08
- Primary completion
- 2024-06-05
- Completion
- 2024-06-05
- First posted
- 2024-02-13
- Last updated
- 2025-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06256562. Inclusion in this directory is not an endorsement.